Summary
BRITISH drugs giant Shire Pharmaceuticals was today poised for a major breakthrough in the US market after settling a crucial patent case with American rival Barr Pharmaceuticals on one of its biggest potential blockbuster medicines.
Under the deal, Barr will not now be allowed to launch a copycat generic version of Shire's new attention deficit hyperactivity disorder (ADHD) drug for three years. The agreement gives Shire crucial breathing space in an intensely competitive market.See the full content of this document
Extract
Huge Boost for Shire in Us Patent Case Win
The Footsie-listed company believes Adderall XR, already one of its major earners, will silence controversy over ADHD dru...
See the full content of this document
Sponsored links
